Javelin Pharmaceuticals (JAV) Inactive 10-Q2010 Q2 Quarterly report

Filed: 10 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accessed, accordingl, adhere, announcement, annum, appraisal, ass, assist, ast, automatically, bankruptc, bear, belie, bring, cancelled, cap, classification, complaint, compliance, Concurrently, consideration, consummate, consummation, contemplated, converted, Court, Ct, customary, Dec, defend, Delaware, den, denied, discovery, disruption, Dr, drawn, drew, duty, Dylo, earch, eligibility, exped, expedited, fiduciary, fo, fully, goal, Hospira, identified, iii, illion, incurrence, insolvency, intrinsic, involuntary, IV, Jan, ject, ketorolac, Law, lawsuit, le, leave, maximum, merge, moot, motion, moved, MPI, Myriad, ninety, novative, NSAID, ny, ods, oppose, original, outlined, Parrish, partly, PDUFA, perfected, peri, permitted, predict, Prescription, proceeding, prohibit, promptly, properly, proposed, prospective, purported, reinstated, repaid, repay, roceeding, roprietary, royalty, rth, satisfaction, Schnipper, served, settle, shareholder, soliciting, st, statutory, stipulated, Super, surviving, tender, tendered, travel, unexercised, validly, ved, vigorously, voluntary, waiver, withdrawn

Removed: acquired, attract, Baxter, chain, clarity, collectibility, communicate, comprised, deployment, disclosed, display, distressed, effectively, EITF, eliminating, expensed, FAS, FIFO, forfeited, FSP, generated, greater, healthcare, high, impairment, Implementation, implemented, inactive, labeling, lesser, low, manufacturer, modification, noncredit, nonfinancial, nonrecurring, outlicensing, packaging, Presentation, proceed, production, ranging, receipt, receivable, retained, sampling, secondary, seller, shipping, submission, supplier, UK, unit, validation

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

JAV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Javelin Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Martin J. Driscoll, the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 10, 2010 /s/ Martin J. Driscoll

Name: Martin J. Driscoll

Title: Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies each periodic report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.